Sinovac Biotech annual debt-to-ebitda ratio
2013
2014
2015
2016
2017
2018
2019
2020
2021
Sinovac Biotech Debt-to-EBITDA Ratio Growth & History (SVA)
Sinovac Biotech's debt-to-ebitda ratio was 0.01 for fiscal 2021.
View full Sinovac Biotech company overviewSinovac Biotech annual debt-to-ebitda ratio history
| Fiscal year | Period ended | Debt-to-EBITDA ratio | Change | Growth |
|---|---|---|---|---|
| 2021 | 2021-12-31 | 0.01 | −0.56 | −98.62% |
| 2020 | 2020-12-31 | 0.57 | 0.40 | +238.27% |
| 2019 | 2019-12-31 | 0.17 | 0.02 | +16.39% |
| 2018 | 2018-12-31 | 0.14 | −0.52 | −78.21% |
| 2017 | 2017-12-31 | 0.66 | −6.66 | −90.99% |
| 2016 | 2016-12-31 | 7.32 | 5.05 | +223.17% |
| 2015 | 2015-12-31 | 2.26 | −2.79 | −55.25% |
| 2014 | 2014-12-31 | 5.06 | 1.96 | +63.25% |
| 2013 | 2013-12-31 | 3.10 | — | — |
Sinovac Biotech debt-to-ebitda ratio trends
Over the last five fiscal years, Sinovac Biotech's debt-to-ebitda ratio decreased from 7.32 to 0.01, a change of −7.31.
About the metric
What the debt-to-EBITDA ratio means
Debt-to-EBITDA compares interest-bearing debt with operating earnings before interest, taxes, depreciation, and amortization. It is commonly used to assess leverage, but it is generally unsuitable for banks and other financial companies.
Calculation and source
How debt-to-EBITDA is calculated
TickerStat divides period-end total debt by annual EBITDA. Quarterly observations use trailing-12-month EBITDA. Periods with zero or negative EBITDA are excluded because the leverage multiple would not be meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sinovac Biotech source filings ↗